119 related articles for article (PubMed ID: 8112634)
1. A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer.
Markman M
Gynecol Oncol; 1993 Dec; 51(3):297-8. PubMed ID: 8112634
[No Abstract] [Full Text] [Related]
2. Tumor associated trypsin inhibitor and CA-125 during treatment of mucinous ovarian cancer in 2 patients.
Mogensen O
Eur J Cancer; 1991; 27(9):1180-1. PubMed ID: 1659852
[No Abstract] [Full Text] [Related]
3. Toward a chronotherapy of ovarian cancer with taxol. Part I: Basic background.
Cornélissen G; Halberg E; Long HJ; Prem K; Bakken E; Touitou Y; Elg S; Haus E; Halberg F
Chronobiologia; 1991; 18(4):153-66. PubMed ID: 1687729
[No Abstract] [Full Text] [Related]
4. Resetting the CA-125 range for a complete response to chemotherapy: why?
Markman M
Gynecol Oncol; 1994 Jun; 53(3):281-2. PubMed ID: 8206398
[No Abstract] [Full Text] [Related]
5. [CA-125: a serum tumor marker in ovarian cancer].
Cohen AD; Piura B; Cohen Y
Harefuah; 1994 Feb; 126(3):154-9. PubMed ID: 8168751
[No Abstract] [Full Text] [Related]
6. The reassessment of ovarian cancer in complete clinical remission: what are our goals?
Clarke-Pearson DL
Gynecol Oncol; 1994 Feb; 52(2):151-3. PubMed ID: 8314131
[No Abstract] [Full Text] [Related]
7. Power of chronobiologic pilots: a statistician's opinion.
Berry DA
Chronobiologia; 1993; 20(3-4):213-8. PubMed ID: 8131670
[No Abstract] [Full Text] [Related]
8. [CA 125 in diagnosis and prognosis of epithelial ovarian cancer].
Cohen AD; Piura B; Cohen Y; Shoenfeld Y
Harefuah; 1994 Mar; 126(5):283-5, 303. PubMed ID: 8188111
[TBL] [Abstract][Full Text] [Related]
9. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.
Markman M; Kennedy A; Kim J
Gynecol Oncol; 2001 Dec; 83(3):593-5. PubMed ID: 11733977
[TBL] [Abstract][Full Text] [Related]
11. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
Tuxen MK; Sölétormos G; Dombernowsky P
Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
[TBL] [Abstract][Full Text] [Related]
12. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
13. An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma.
Gard GB; Houghton CR
Gynecol Oncol; 1994 Jun; 53(3):283-9. PubMed ID: 8206399
[TBL] [Abstract][Full Text] [Related]
14. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Markman M
Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
[No Abstract] [Full Text] [Related]
15. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
Nagele F; Vavra N; Kurz C; Sevelda P
Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
[TBL] [Abstract][Full Text] [Related]
16. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
[TBL] [Abstract][Full Text] [Related]
18. Monitoring CA 125 serum levels during early chemotherapy is an excellent prognostic method in advanced ovarian cancer.
Högberg T; Kågedal B
Gynecol Oncol; 1993 Mar; 48(3):413-4. PubMed ID: 8462909
[No Abstract] [Full Text] [Related]
19. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
20. Echography and CA 125 in ovarian pathology. Preliminary data of a new score.
Foglia M; Verri PG; Calabrese A; Corongiu F; Tarani A; Margiaria ML; De Pascale A; Tagliati D
J Nucl Med Allied Sci; 1990; 34(4 Suppl):67-70. PubMed ID: 2092152
[No Abstract] [Full Text] [Related]
[Next] [New Search]
